stockportfolio.pro
Stocks / MANE vs VCYT
MANE vs VCYT
Veradermics, Incorporated and Veracyte, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Veradermics, Incorporated (MANE) | Veracyte, Inc. (VCYT) | |
|---|---|---|
| Market cap | $4.0B | $3.9B |
| Revenue (latest FY) | $0 | $517.14M |
| Net income (latest FY) | $-70.00M | $66.35M |
| Revenue growth (5y CAGR) | — | 34.5% |
| Net margin | — | 12.8% |
| Return on equity | 57.8% | 5.1% |
| P/E ratio | — | 44.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MANE — free Open VCYT — freeFrequently asked questions
Which is bigger, MANE or VCYT?
Veradermics, Incorporated is larger by market capitalization — $4.0B versus $3.9B.
Which grows faster, MANE or VCYT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.